Unknown PHASE3 INTERVENTIONAL NCT00223613

Intranasal Insulin for Prevention of Type 1 Diabetes

Intranasal Insulin for Prevention of Type 1 Diabetes in Children Carrying Increased HLA-Conferred Genetic Risk

Sponsor: Oulu University Hospital

Interventions daily intranasal administration of insulin

Updated 7 times since 2017 Last updated: Sep 18, 2006 Started: Aug 31, 1997 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00223613, this PHASE3 trial focuses on Type 1 Diabetes and remains ongoing. Sponsored by Oulu University Hospital, it has been updated 7 times since 1997, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Apr 2020 — Jan 2021 [monthly]

Unknown Status PHASE3
Apr 2019 — Apr 2020 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Aug 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oulu University Hospital
Tampere University
University of Helsinki
University of Turku

Data source: University of Turku

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Turku, Finland